SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYREAccesswire • Tuesday
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYREAccesswire • 12/17/24
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Shareholders to Learn More About the InvestigationAccesswire • 12/04/24
SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 12/04/24
Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the InvestigationAccesswire • 12/03/24
Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Shareholders to Inquire about Securities InvestigationAccesswire • 12/02/24
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A AntibodiesPRNewsWire • 12/02/24
Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Shareholders to ConnectAccesswire • 12/01/24
Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities InvestigationAccesswire • 11/29/24
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the InvestigationAccesswire • 11/28/24
Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationAccesswire • 11/27/24
Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to ConnectAccesswire • 11/26/24
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx ConferencePRNewsWire • 11/25/24
Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Stockholders to ConnectAccesswire • 11/25/24
Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the InvestigationAccesswire • 11/24/24
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Stockholders to Learn More About the InvestigationAccesswire • 11/22/24
Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities InvestigationAccesswire • 11/21/24
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach OutAccesswire • 11/20/24
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common StockPRNewsWire • 11/19/24
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded WarrantsPRNewsWire • 11/18/24
Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance DosingPRNewsWire • 11/12/24
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024PRNewsWire • 11/11/24
Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatePRNewsWire • 11/07/24
